Pharmaceutical intermediates
Roflumilast Intermediates
3 pharmaceutical intermediates for Roflumilast. Indication: Seborrheic dermatitis; Plaque psoriasis; Chronic obstructive pulmonary disease.
About Roflumilast
- Originator
- Takeda Pharmaceutical Inc
- Indication
- Seborrheic dermatitis; Plaque psoriasis; Chronic obstructive pulmonary disease
- Approved Date
- 01/23/2018
Available intermediates
3 intermediates currently listed for Roflumilast. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| 4-Difluoromethoxy-3-hydroxybenzaldehyde | 151103-08-1 | / | / |
| 4-(DIFLUOROMETHOXY)-3-(CYCLOPROPYLMETHOXY)-BENZALDEHYDE | 151103-09-2 | / | / |
| Methyl 4-(difluoroMethoxy)-3-hydroxybenzoate | 1159429-52-3 | / | / |
Other programs under R
Building toward Roflumilast?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →